Half-year report · HY
7446.TEDINET S100Y3KO
Period2025-10-01 → 2026-03-31
Filed2026-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.9bn | 2025-10-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥34.4bn | 2024-10-01 → 2025-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.8bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Operating income | ¥530m | 2025-10-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥325m | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥565m | 2025-10-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥595m | 2024-10-01 → 2025-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥355m | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥576m | 2025-10-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥400m | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥396m | 2025-10-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥429m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥269m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥400m | 2025-10-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥273m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥20.4bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥18.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥18.5bn | at 2025-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.8bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥10.4bn | at 2025-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥8.5bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.7bn | at 2025-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.7bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥925m | at 2025-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.7bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥911m | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-09-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.9bn | 2025-10-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥150m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥674m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥33m | 2025-10-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥19m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥62m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥53m | 2025-10-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥6m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥439.52 | 2025-10-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥475.93 | 2024-10-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥298.4 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.5% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.0% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Academia Life Science Sales Groupreportable segment | revenue | 2025-10-01 → 2026-03-31 | ¥1.3bn |
| Academia Life Science Sales Groupreportable segment | revenue external | 2025-10-01 → 2026-03-31 | ¥1.3bn |
| Industry Sales Groupreportable segment | revenue | 2025-10-01 → 2026-03-31 | ¥9.6bn |
| Industry Sales Groupreportable segment | revenue external | 2025-10-01 → 2026-03-31 | ¥9.6bn |
| Medical Sales Groupreportable segment | revenue | 2025-10-01 → 2026-03-31 | ¥8.0bn |
| Medical Sales Groupreportable segment | revenue external | 2025-10-01 → 2026-03-31 | ¥8.0bn |
| —segment total | revenue | 2025-10-01 → 2026-03-31 | ¥18.9bn |
| —segment total | revenue external | 2025-10-01 → 2026-03-31 | ¥18.9bn |
| Academia Life Science Sales Groupreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥1.5bn |
| Academia Life Science Sales Groupreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥1.5bn |
| Industry Sales Groupreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥9.1bn |
| Industry Sales Groupreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥9.1bn |
| Medical Sales Groupreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥7.2bn |
| Medical Sales Groupreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥7.2bn |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥17.8bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥17.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 510
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for directors retirement benefits sga | Prior1InterimDuration | 5635000 | JPY |
| Provision for directors retirement benefits sga | InterimDuration | 5749000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | 9146308000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | 7194887000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1465687000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 17806883000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 17806883000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | 9146308000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | 7194887000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1465687000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 17806883000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 17806883000 | JPY |
| Gross profit | Prior1InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | 826015000 | JPY |
| Gross profit | Prior1InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | 678786000 | JPY |
| Gross profit | Prior1InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 174592000 | JPY |
| Gross profit | Prior1InterimDuration_ReportableSegmentsMember | 1679394000 | JPY |
| Gross profit | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Gross profit | Prior1InterimDuration | 1679394000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | 9608092000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | 8027884000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1306176000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 18942154000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 18942154000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | 9608092000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | 8027884000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1306176000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 18942154000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | InterimDuration | 18942154000 | JPY |
| Gross profit | InterimDuration_jpcrp040300-ssr_E02810-000IndustrySalesGroupReportableSegmentMember | 905864000 | JPY |
| Gross profit | InterimDuration_jpcrp040300-ssr_E02810-000MedicalSalesGroupReportableSegmentMember | 777211000 | JPY |
| Gross profit | InterimDuration_jpcrp040300-ssr_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 175976000 | JPY |
| Gross profit | InterimDuration_ReportableSegmentsMember | 1859052000 | JPY |
| Gross profit | InterimDuration_ReconcilingItemsMember | － | JPY |
| Gross profit | InterimDuration | 1859052000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |